Am-Telsan (amlodipine + telmisartan): Uses, Dosage & Side Effects

What it's for (Indications)

Amlodipine + Telmisartan is a fixed-dose combination medication primarily indicated for the treatment of essential hypertension (high blood pressure).
It is typically prescribed for patients whose blood pressure is not adequately controlled with either amlodipine or telmisartan monotherapy, or as initial therapy in patients likely to need multiple agents to achieve their blood pressure goals.
This combination therapy offers a comprehensive approach to blood pressure management by targeting different physiological pathways involved in hypertension, thereby enhancing antihypertensive efficacy and potentially improving patient compliance compared to taking separate medications.
The dual mechanism addresses both direct vasodilation and blockade of the renin-angiotensin-aldosterone system, providing robust blood pressure control.

Dosage Information

Type	Guideline
Standard	The dosage of amlodipine + telmisartan should be individualized based on the patient's existing antihypertensive regimen, clinical response, and tolerability, with careful consideration of the patient's renal and hepatic function. This fixed-dose combination is usually administered orally once daily, with or without food. Available strengths typically include amlodipine 5 mg combined with telmisartan 40 mg or 80 mg, and amlodipine 10 mg combined with telmisartan 40 mg or 80 mg. Patients transitioning from monotherapy should be initiated on a dose that provides adequate blood pressure control without excessive adverse effects. Dose adjustments should be made gradually, and blood pressure should be regularly monitored to achieve optimal therapeutic outcomes.

Type

Guideline

Standard

The dosage of amlodipine + telmisartan should be individualized based on the patient's existing antihypertensive regimen, clinical response, and tolerability, with careful consideration of the patient's renal and hepatic function. This fixed-dose combination is usually administered orally once daily, with or without food. Available strengths typically include amlodipine 5 mg combined with telmisartan 40 mg or 80 mg, and amlodipine 10 mg combined with telmisartan 40 mg or 80 mg. Patients transitioning from monotherapy should be initiated on a dose that provides adequate blood pressure control without excessive adverse effects. Dose adjustments should be made gradually, and blood pressure should be regularly monitored to achieve optimal therapeutic outcomes.

Safety & Warnings

Common Side Effects

Commonly reported side effects associated with amlodipine + telmisartan combination therapy include peripheral edema (swelling of the ankles/feet, primarily due to the amlodipine component), dizziness, headache, flushing, fatigue, and palpitations.
Other potential side effects may include orthostatic hypotension, gastrointestinal disturbances (e.
g.
, nausea, abdominal pain), and muscle cramps.
Less common but more serious adverse events can include hyperkalemia, particularly in patients with renal impairment or those taking potassium-sparing diuretics or supplements.
Renal function deterioration, angioedema (rarely), and hepatic dysfunction have also been reported.
Patients should be advised to report any persistent or worsening side effects to their healthcare provider for evaluation and appropriate management.

Serious Warnings

Black Box Warning: **WARNING: FETAL TOXICITY** Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue amlodipine + telmisartan as soon as pregnancy is detected. There is a critical period of vulnerability during the second and third trimesters of pregnancy. The use of telmisartan during the second and third trimesters of pregnancy is associated with oligohydramnios, which can result in fetal lung hypoplasia, skeletal deformations, and death. If pregnancy is detected, amlodipine + telmisartan should be discontinued as soon as possible. Neonates with a history of *in utero* exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. These adverse effects are directly attributable to the telmisartan component of the combination drug.
Several significant warnings are associated with amlodipine + telmisartan.
Patients, particularly those who are volume-depleted or on high-dose diuretics, may experience symptomatic hypotension, especially after the initial dose.
Caution is advised in patients with impaired renal function, as telmisartan can exacerbate renal impairment, and hyperkalemia risk increases; therefore, regular monitoring of serum creatinine and potassium is crucial.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by combining telmisartan with ACE inhibitors or aliskiren is generally not recommended due to increased risks of hypotension, hyperkalemia, and renal function changes.
Patients with severe aortic stenosis or obstructive hypertrophic cardiomyopathy should be managed with caution due to the vasodilatory effects.
Hepatic impairment also requires careful consideration due to the metabolism and elimination pathways of both components.

How it Works (Mechanism of Action)

Amlodipine + telmisartan combines two antihypertensive agents with distinct, complementary mechanisms of action. Amlodipine, a dihydropyridine calcium channel blocker, primarily reduces blood pressure by inhibiting the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. This leads to direct arterial vasodilation and a reduction in peripheral vascular resistance and afterload. Telmisartan, an angiotensin II receptor blocker (ARB), selectively blocks the binding of angiotensin II to the AT1 receptor. This blockade inhibits the potent vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation, decreased aldosterone production, sodium and water excretion, and ultimately a reduction in blood pressure. The synergistic effect of these two drugs provides enhanced antihypertensive efficacy compared to monotherapy.